Back to Newsroom
Back to Newsroom

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

Thursday, 21 September 2023 08:25 PM

Aytu BioPharma, Inc.

ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.

Conference Call Information

Date and Time: Wednesday, September 27, 2023, at 4:30 pm ET

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 or (973) 528-0011 using the participant access code 381283.

Webcast Information: The webcast will be accessible live and archived at the following link, https://www.webcaster4.com/Webcast/Page/2142/48975 and on Aytu BioPharma's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.

Replay: A teleconference replay of the call will be available until October 11, 2023 at (877) 481-4010 or (919) 882-2331, replay access code 48975.

About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines and consumer health products addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com.

Contacts for Investors:

Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum or Roger Weiss
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.

Topic:
Conference Call
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: